nirsevimab recommended for infant RSV protection
9 June 2023 Nirsevimab unanimously recommended by FDA Advisory Committee for theprevention of RSV lower respiratory tract disease in infants If approved, nirsevimab would be the first preventive option specifically designed toprotect the broad infant population through its first RSV season Across all clinical endpoints, a single dose of nirsevimab delivered consistent andsustained efficacy against RSV disease vs placebo The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and Sanofi's